目的探讨中性粒细胞相关参数在下肢深静脉血栓形成(lower extremity deep venous thrombosis,LEDVT)的临床应用价值。方法选取2017年6月到2020年6月177例在广西医科大学附属第四医院首诊为LEDVT形成的患者为观察组,记录其入院第1天和接...目的探讨中性粒细胞相关参数在下肢深静脉血栓形成(lower extremity deep venous thrombosis,LEDVT)的临床应用价值。方法选取2017年6月到2020年6月177例在广西医科大学附属第四医院首诊为LEDVT形成的患者为观察组,记录其入院第1天和接受治疗2周后的中性粒细胞百分数(N%)、中性粒细胞绝对值(N)、中性粒细胞绝对值/淋巴细胞绝对值(NLR),并将患者按发病时间分为急性组和慢性组;177例同期健康体检者为对照组。比较分析各组各个指标的价值。结果观察组的N%、N、NLR均明显高于对照组,差异有统计学意义(P<0.01)。N和NLR联合诊断LEDVT的灵敏度是85.9、特异度是65.4,ROC是0.858。治疗后各指标均有明显下降。结论 N联合NLR在LEDVT的诊断中有一定意义,动态观察中性粒细胞N%、N、NLR参数可以预测疗效。展开更多
AIM： TO assess feasibility, tolerability and efficacy of gemcitabine-based chemotherapy in patients ≥ 75 years old with advanced pancreatic cancer. METHODS： All consecutive patients ≥ 75 years old with advanced pa...AIM： TO assess feasibility, tolerability and efficacy of gemcitabine-based chemotherapy in patients ≥ 75 years old with advanced pancreatic cancer. METHODS： All consecutive patients ≥ 75 years old with advanced pancreatic adenocarcinoma were included in this retrospective study. Necessary criteria to receive chemotherapy were： performance status 0-2, adequate biological parameters and no serious comorbidities. Other patients received best supportive care （BSC）. RESULTS： Thirty-eight patients （53% women, median age 78 years, range 75-84） with pancreatic cancer （metastatic： n = 20, locally advanced： n = 18） were studied. Among them, 30 （79%） were able to receive chemotherapy [median number： 9 infusions （1-45）]. Six patients （23%） had at least one episode of grade 3 neutropenia and one patient developed a grade 3 hemolytic-uremic syndrome. No toxic death occurred. Three patients （11%） had a partial tumor response, 13 （46%） had a stable disease and 12 （43%） had a tumor progression. Median survival was 9.1 mo （metastatic： 6.9 too, locally advanced： 11.4 too）. CONCLUSION： Tolerance and efficacy of gemcitabinebased chemotherapy is acceptable in elderly patients in good condition, with similar results to younger patients.展开更多
文摘AIM： TO assess feasibility, tolerability and efficacy of gemcitabine-based chemotherapy in patients ≥ 75 years old with advanced pancreatic cancer. METHODS： All consecutive patients ≥ 75 years old with advanced pancreatic adenocarcinoma were included in this retrospective study. Necessary criteria to receive chemotherapy were： performance status 0-2, adequate biological parameters and no serious comorbidities. Other patients received best supportive care （BSC）. RESULTS： Thirty-eight patients （53% women, median age 78 years, range 75-84） with pancreatic cancer （metastatic： n = 20, locally advanced： n = 18） were studied. Among them, 30 （79%） were able to receive chemotherapy [median number： 9 infusions （1-45）]. Six patients （23%） had at least one episode of grade 3 neutropenia and one patient developed a grade 3 hemolytic-uremic syndrome. No toxic death occurred. Three patients （11%） had a partial tumor response, 13 （46%） had a stable disease and 12 （43%） had a tumor progression. Median survival was 9.1 mo （metastatic： 6.9 too, locally advanced： 11.4 too）. CONCLUSION： Tolerance and efficacy of gemcitabinebased chemotherapy is acceptable in elderly patients in good condition, with similar results to younger patients.
